Mohamed Azmi Ahmad Hassali1, Sohail Ayaz Muhammad2, Shahid Shah3, Sameen Abbas4, Irfhan Ali Bin Hyder Ali5, Ahmad Salman6. 1. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia , Penang, Malaysia. 2. School of Management Sciences, University Sains Malaysia , Penang, Malaysia. 3. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Government College University , Faisalabad, Pakistan. 4. Department of Pharmacy, Quaid e Azam University Islamabad , Islamabad, Pakistan. 5. Respiratory Department, Hospital Pulau Pinang, Penang, Ministry of Health Malaysia , Penang, Malaysia. 6. School of Management, COMSATS University Islamabad , Islamabad, Pakistan.
Abstract
Background: Lack of information about economic burden of COPD is a major cause of lack of attention to this chronic condition from governments and policymakers. Objective: To find the economic burden of COPD in Asia, USA and Europe, and to identify the key cost driving factors in management of COPD patients. Methodology: Relevant studies assessing the cost of COPD from patient perspective or societal perspective were retrieved by thoroughly searching PUBMED, SCIENCE DIRECT, GOOGLE SCHOLAR, SCOPUS, and SAGE Premier Databases. Results: In the USA annual per patient direct medical cost and hospitalization cost were reported as $10,367 and $6852, respectively. In Asia annual per patient direct medical cost in Iran, Korea and Singapore was reported as $1544, $3077, and $2335, respectively. However, annual per patient hospitalization cost in Iran, Korea, Singapore, India, China, and Turkey was reported as $865, $1371, $1868, $296, $1477 and $1031, respectively. In Europe annual per patient direct medical cost was reported as $11,787, $10,552, $8644, $8203, $7760, $3190, $1889, $2162, and $2254 in Norway, Denmark, Germany, Italy, Sweden, Greece, Spain, Belgium, and Serbia, respectively. Conclusion: Limiting the disease to early stage and preventing exacerbations may reduce the cost of management of COPD.
Background: Lack of information about economic burden of COPD is a major cause of lack of attention to this chronic condition from governments and policymakers. Objective: To find the economic burden of COPD in Asia, USA and Europe, and to identify the key cost driving factors in management of COPDpatients. Methodology: Relevant studies assessing the cost of COPD from patient perspective or societal perspective were retrieved by thoroughly searching PUBMED, SCIENCE DIRECT, GOOGLE SCHOLAR, SCOPUS, and SAGE Premier Databases. Results: In the USA annual per patient direct medical cost and hospitalization cost were reported as $10,367 and $6852, respectively. In Asia annual per patient direct medical cost in Iran, Korea and Singapore was reported as $1544, $3077, and $2335, respectively. However, annual per patient hospitalization cost in Iran, Korea, Singapore, India, China, and Turkey was reported as $865, $1371, $1868, $296, $1477 and $1031, respectively. In Europe annual per patient direct medical cost was reported as $11,787, $10,552, $8644, $8203, $7760, $3190, $1889, $2162, and $2254 in Norway, Denmark, Germany, Italy, Sweden, Greece, Spain, Belgium, and Serbia, respectively. Conclusion: Limiting the disease to early stage and preventing exacerbations may reduce the cost of management of COPD.
Entities:
Keywords:
COPD; direct medical cost; economic burden; systematic review
Authors: Anees Ur Rehman; Mohamed Azmi Ahmad Hassali; Sabariah Noor Harun; Sameen Abbas; Jaya Muneswarao; Irfhan Ali Bin Hyder Ali; Rabia Hussain Journal: Health Qual Life Outcomes Date: 2020-05-13 Impact factor: 3.186